Patent: 9,540,410
✉ Email this page to a colleague
Summary for Patent: 9,540,410
Title: | Gemcitabine prodrugs and uses thereof |
Abstract: | The present invention provides compounds according to formula I: ##STR00001## and pharmaceutically acceptable salts thereof. For compounds of formula I, R.sup.1 and R.sup.2 are independently selected from the group consisting of H, --C(.dbd.O)--(CH.sub.2).sub.2-aryl, and --C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)--NH-aryl. The subscript n is from 2 to 6. R.sup.3 is selected from the group consisting of H and --C(.dbd.O)--O--R.sup.4; and R.sup.4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl. Compounds are provided wherein at least one of R.sup.1 and R.sup.2 is other than H. Pharmaceutical compositions, methods for inhibiting the growth of cancer cells, and methods for the treatment of cancer are also provided. |
Inventor(s): | Wu; Laurence I. (Taipei, TW) |
Assignee: | BOYEN THERAPEUTICS, INC. (Taipei, TW) |
Application Number: | 14/599,166 |
Patent Claims: | see list of patent claims |
Details for Patent 9,540,410
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2032-11-13 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2032-11-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |